MAPT and Alzheimer disease: It is worth noting that 18F-Florzolotau has shown favorable affinity to all types of tau aggregates [21] and is able to detect tau deposition in vivo in the brains of patients with different tauopathies (i.e., three- and four-repeat (3R/4R) tau in AD [49–51], 4R-tau in progressive supranuclear palsy [31, 52], 4R and 3R/4R-tau in frontotemporal lobar degeneration with tauopathy caused by microtubule-associated protein tau mutations [53]) while 18F-MK6240 and 18F-flortaucipir have relatively low affinity for non-AD tauopathies [54–56].